ReviewBMC cardiovascular disorders2025
Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review.
Review in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined PD-1/CTLA-4 blockade improves overall survival in advanced cancers but increases the risk of severe myocarditis. Iparomlimab and Tuvonralimab (Qibian®), a novel bifunctional anti-PD-1/CTLA-4 antibody, has recently entered clinical use, though its cardiotoxicity profile remains largely unknown. No myocarditis cases have been formally reported with this regimen. CASE PRESENTATION: A 61-year-old woman with ovarian cancer developed generalized malaise, dyspnea, and chest tightness after the second cycle of Iparomlimab and Tuvonralimab. Elevated high-sensitivity cardiac troponin T (hs-cTnT) levels and new electrocardiographic abnormalities were detected. Empirical methylprednisolone therapy (2 mg/kg/day) was initiated. Following the exclusion of acute coronary syndrome by angiography, ICI-induced myocarditis was diagnosed based on the patient’s symptoms, elevated troponin, electrocardiographic abnormalities, and applicable international consensus criteria (ESC/ICOS). Treatment was escalated to include high-dose methylprednisolone pulse (1 g/day), intravenous immunoglobulin, and mycophenolate mofetil. The patient stabilized by day 24 and was discharged. Persistent cardiac dysfunction warranted the implantation of a cardioverter-defibrillator and permanent discontinuation of immune checkpoint inhibitors.
conclusionWe report the first documented case of myocarditis linked to the novel bifunctional PD-1/CTLA-4 combination, Iparomlimab and Tuvonralimab. This case highlights that structural drug optimizations do not preclude severe cardiotoxicity. In resource-limited settings lacking advanced imaging, serial high-sensitivity troponin monitoring served as the cornerstone for early detection and guiding management. This experience confirms that favorable outcomes are achievable through vigilant biomarker surveillance and coordinated multidisciplinary care, even without advanced diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.